drugset
drugset / Trial / NCT05844449

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

NCT05844449 ↗

Phase 3 Enrolling by invitation 174 enrolled Vertex Pharmaceuticals Incorporated
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) in participants with cystic fibrosis (CF).

Timeline

Start
2023-08-11
Primary completion
2029-07-30
Completion
2029-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject VNZ/TEZ/D-IVA Unknown — Oral

Indications

cystic fibrosis